Study design
ICH, Przychodnia, Cancer
SOLID TUMORS, CANCER
Divarasib plus cetuximab combination data are reported from arm C of an ongoing phase 1b, open-label, multicenter, dose-escalation and dose-expansion study of divarasib in combination with other anticancer therapies in patients with advanced or metastatic solid tumors that harbor a Patients received oral divarasib 200 or 400 mg once daily and intravenous cetuximab (400 mg/mThis study was conducted in full conformance with the ICH E6 guideline for Good Clinical Practice and the Declaration of Helsinki, or the applicable laws and regulations of the country in which the research is conducted, whichever affords the greater protection to the individual. The protocol was approved by the institutional review boards at City of Hope Comprehensive Cancer Center, Princess Margaret Cancer Center, Peter MacCallum Cancer Center, Jewish General Hospital, Universitair Medisch Centrum Utrecht, Biokinetica Przychodnia Jozefow, Istituto Scientifico Romagnolo per lo Studio y la Cura dei Tumori, Asst Grande Ospedale Metropolitano Niguarda, UZ Antwerpen, Hospital Universitario Virgen Del Rocio, Hospital Universitari Vall D’hebron, Seoul National University Hospital, Seoul National University Bundang Hospital, Hospital Clinico Universitario De Valencia, Hospital Universitario 12 De Octubre, Sheba Medical Center and Abramson Cancer Center. Patients provided signed informed consent before enrollment.